Tau Pet Imaging in the Aging Brain Cohort Dedicated to Diversity Study

Last updated: January 9, 2025
Sponsor: University of Pennsylvania
Overall Status: Active - Recruiting

Phase

N/A

Condition

Mental Disability

Dementia

Mild Cognitive Impairment

Treatment

[18F]AV-1451

Clinical Study ID

NCT05393388
844403
  • Ages > 65
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

We will conduct a Tau PET scan in cognitively normal older adults, enrolled in the Aging Brain Cohort Dedicated to Diversity Study (ABCD2-Tau) study at the University of Pennsylvania's Penn Memory Center/Alzheimer's Disease Core Center (PMC/ADC).Study duration will generally be a one-day study visit for PET imaging, but all subjects will be followed annually as part of their participation in the ABCD2 study. Findings from this study will likely provide insight into the mechanisms and distinctions of age-related cognitive decline and that of preclinical Alzheimer's Disease.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Males and females African Americans ≥ 65 years of age.

  2. Part of the ABCD2 longitudinal cohort, protocol 844047, of the PMC/ADCC withconsensus conference designation of normal cognition.

  3. ABCD2 longitudinal visit must be completed or scheduled to be completed within 1year prior to the [18F]AV-1451 TAU PET scan.

  4. A brain MRI must be performed within 1 year prior to their study [18F]AV-1451 TAUPET scan date and be deemed of adequate quality that the scan may be used for studyanalysis, including 3T high-resolution imaging of medial temporal lobe structures.

  5. An amyloid PET scan completed or scheduled within 1year of their study [18F]AV-1451

  6. Women must be post-menopausal or surgically sterile.

Exclusion

Exclusion Criteria:

  1. Have any medical or psychiatric conditions that, in the opinion of the investigator,would compromise the subject's safety or successful participation in the study,including major depression and prior head trauma.

  2. Have evidence of structural abnormalities such as major stroke or mass on MRI thatis likely to interfere with analysis of the PET scan.

  3. Inability to tolerate or contraindication to imaging procedures in the opinion of aninvestigator or treating physician.

  4. Have a history of significant ongoing alcohol or substance abuse or dependence basedon self-report.

  5. Women of child bearing potential

  • The inclusion / exclusion criteria will be ascertained through self-report inconjunction with any medical history available through the participant'smedical or research records (EPIC or the ADC database)*

Study Design

Total Participants: 160
Treatment Group(s): 1
Primary Treatment: [18F]AV-1451
Phase:
Study Start date:
May 09, 2022
Estimated Completion Date:
May 31, 2027

Connect with a study center

  • Hospital of the University of Pennsylvania - Penn Memory Center

    Philadelphia, Pennsylvania 19104
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.